Canine Studies to Restore Endogenous Insulin

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43DK079434-01A2
Agency Tracking Number: DK079434
Amount: $277,416.00
Phase: Phase I
Program: SBIR
Awards Year: 2009
Solicitation Year: 2009
Solicitation Topic Code: N/A
Solicitation Number: PHS2009-2
Small Business Information
MITOKINE BIOSCIENCE, LLC
MITOKINE BIOSCIENCE, LLC, PO Box 275, HANCOCK, ME, 04640
DUNS: 785834164
HUBZone Owned: Y
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 B LIGON
 (207) 422-6838
 BLIGON@MITOKINE.COM
Business Contact
 B LIGON
Phone: (207) 422-6838
Email: bligon@mitokine.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Identifying a safe, oral treatment capable of both restoring the natural mechanisms that regenerate pancreatic beta cells and improving function would be a major advance in therapeutic options for diabetes. The objective of the proposed research is to test the hypothesis that oral administration of a natural beta cell product, that has been depleted by the disease, will result in improved beta cell function as measured by Cpeptide, fasting glucose, glycosylated hemoglobin and fructosamine. Twelve companion dogs that are naturally insulin-dependent will be studied in collaboration with the Clinical Sciences Department at Purdue University School of Veterinary Medicine. The aims of this research are 1) to test the feasibility and safety of this new diabetes therapy by measuring glycemic control before and after treatment and 2) test the pharmacokinetics of the treatment at various dosages. The long-term goal is to provide an oral product for both veterinary and human diabetes that offers sustained resolution of blood glucose abnormalities by restoring endogenous insulin without side effects or toxicity. PUBLIC HEALTH RELEVANCE: The proposed research will test the hypothesis that restoring a natural product of the cells that make insulin will improve their function and the symptoms of diabetes. The project will assess whether this treatment offers sustained improvement in glucose control without side effects or toxicity. If proven safe and effective, this treatment could be a major advance forward in therapeutic interventions for both type 1 and type 2 diabetes.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government